Serotonergic System and Violent Video Games

Healthy Volunteers Clinical Trial

— Serogen  

Official title:

Genetic-pharmacological Neuroimaging of the Serotonergic System in Violent Video Games

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01644071
• Other study ID #: CTC-A_12-023
• Status: Completed
• Phase: N/A
• First received: June 20, 2012
• Last updated: September 28, 2015
• Start date: February 2012
• Est. completion date: June 2014

Study information

• Verified date: September 2015
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Aggressive behavior (AB) is a major burden to society with severe socio-economic consequences. Genetic studies suggest a high heritability of AB; in particular, the low expressing allele of the MAOA gene (MAOA-L) has been associated with increased AB. Recent neural aggression models have suggested a dysfunctional emotion regulation circuit including amygdala, orbitofrontal, and anterior cingulate cortex. Dysregulated serotonergic (5-HT) projections from the anterior cingulate cortex to the amygdala have been suggested to promote aggressive behavior. This finding is well in line with the observation that the MAOA-L allele leads to a reduced expression of monoamine oxidase A and thus to an overflow of 5-HT in serotonergic cortico-amygdalar projections. However, due to methodological and ethical constraints, the neural substrates of AB are difficult to assess. A possible solution is the use of virtual violence which permits AB against virtual characters without direct consequences for any real person and can be easily applied in functional imaging experiments. There is evidence that virtual and real aggression share common neural substrates. AB in violent video games inhibits rostral anterior cingulate cortex (ACC) and amygdala in line with the suggested neurophysiological circuits underlying real-life AB.

Description:

Our study plan comprises the assessment of brain activation patterns during virtual AB in a violent video game with functional magnetic resonance imaging under three experimental conditions in randomized, double-blind fashion:

1. Increase of synaptic 5-HT with a selective serotonin reuptake inhibitor (SSRI, Cipralex ®);

2. reduction of synaptic 5-HT with the Rapid Tryptophan Depletion Test (RTD); and 3) Placebo.

A blood sample genotyping will assess the allelic expression of the MAOA gene. We hypothesize

1. a modification of the ACC-amygdala system by the serotonergic intervention and

2. an interaction with the genotype concerning the MAOA gene. The results of this study will give valuable insights into the neurogenetic biology underlying aggression which will open new perspectives for therapeutical and pharmacological intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: June 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• male

• age 18-60 (adults), age 12-17 (juveniles)

• right-handedness

• German native language

Exclusion Criteria:

• any contraindications against MR investigations

• any contraindications against application of SSRIs

• any history of neurological or psychiatric illness

• history of drug abuse

• history of psychopharmacological therapy

Study Design

Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• cipralex
one time 10 mg, tablet

Locations

Country	Name	City	State
Germany	Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Aachen	Aachen

Sponsors (1)

Lead Sponsor	Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	functional neuroimaging		1 day	No